home icon
search icon
menu icon
dr.

Muhammad Rizki Yaznil

M.Ked(OG), Sp.O.G, Subsp.Onk
Muhammad Rizki Yaznil

dr. Muhammad Rizki Yaznil, M.Ked(OG), Sp.O.G, Subsp.Onk

Employee ID Number

198208302008011003

National Lecturer Registration Number

0030088201

Study Program
Program Studi Sp-1 Obstetri dan Ginekologi
Program Studi Profesi Dokter
Field Of Knowledge
Positions
Assistant Professor - Upper
Research Media
Contacts:
E-mail

rizki.yaznil@usu.ac.id, rizkiyaznil@gmail.com

Office Address

Jln. Cardiac Center, 1st floor Pavilion Building H. Adam Malik General Hospital

Curriculum Vitae file_download

National Publications

Quality of life among ovarian cancer survivors in Haji Adam Malik General Hospital Medan, Indonesi

MUHAMMAD OKY PRABUDI , MUHAMMAD RIZKI YAZNIL , LILI ROHMAWATI

International Publications

Tamoxifen-associated Endometrial Cancer after Treatment in Young Premenopausal Women with Breast Cancer: A Case Report

MUHAMMAD RIZKI YAZNIL

Mothers’ knowledge, attitude, and behavior regarding child immunization, and the association with child immunization status in Medan City during the COVID-19 pandemic

MUHAMMAD RIZKI YAZNIL

LIFE Literature for ENYGO

MUHAMMAD RIZKI YAZNIL

Glutathione Peroxidase in Ovarian Cancer Patients

DERI EDIANTO , MOHAMMAD FAUZI SAHIL , EDY ARDIANSYAH , MUHAMMAD RIZKI YAZNIL

Assessment of the Quality of Life for Gynecologic Cancer Patients Using Functional Assessment of Cancer TherapyGeneral (Fact-G) Questionnaire at Haji Adam Malik Hospital

DERI EDIANTO , MUHAMMAD RIZKI YAZNIL , IMAN HELMI EFFENDI

Asian society of gynecologic oncology international workshop 2018

MUHAMMAD RIZKI YAZNIL

The correlation between hemoglobin concentration during pregnancy with the maternal and neonatal outcome

MUHAMMAD RIZKI YAZNIL

Glutathione peroxidase in ovarian cancer patients in Indonesia

MUHAMMAD RIZKI YAZNIL

The correlation of matrix metalloproteinase-9 serum levels with clinicopathological factor in epithelial type ovarian cancer patients

MUHAMMAD RIZKI YAZNIL

Emerging molecular targeted therapies or early preclinical trials in ovarian cancer

MUHAMMAD RIZKI YAZNIL